Research map: Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives

Back to the article

Papers in this map

  1. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial · Hussein A. Tawbi · 2017 · 1480 citations · Cited by this paper
  2. Revolutionizing Breast Cancer Therapeutics: Intersecting Frontiers of Precision Medicine, Nanotechnology, and Drug Delivery Innovations · 2025 · Related
  3. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives · Marta Sbaraglia · 2020 · 1138 citations · Cited by this paper
  4. Cardiotoxicity of Targeted Therapies in Hematologic Malignancies: From Molecular Mechanisms to Clinical Management · 2026 · Related
  5. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours · Maria Fernanda Amary · 2011 · 1034 citations · Cited by this paper
  6. Second-Line Treatment in cholangiocarcinoma - Current State of the Art and Future Perspectives · 2025 · Related
  7. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial · Anas Younes · 2016 · 931 citations · Cited by this paper
  8. Navigating PARP Inhibitor Resistance in Ovarian Cancer: Bridging Mechanistic Insights To Clinical Translation · 2025 · Related
  9. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma · Ingo K. Mellinghoff · 2023 · 808 citations · Cited by this paper
  10. Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML · 2025 · Related
  11. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism · Xiaolin Wan · 2006 · 759 citations · Cited by this paper
  12. Transforming a Roadblock into a Roadmap: Evolving HFSR Management From Adverse Event to Efficacy Biomarker · 2026 · Related
  13. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5 · Konstantinos J. Mavrakis · 2016 · 605 citations · Cited by this paper
  14. The Use of Targeted Therapy in Pediatric Acute Lymphoblastic Leukemia: Exploring Novel Approaches and Emerging Therapies · 2026 · Related
  15. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome · Twinkal C. Pansuriya · 2011 · 572 citations · Cited by this paper
  16. Advanced Mucosal Melanoma Therapies: Current Status and Future Directions · 2026 · Related
  17. The parallel lives of angiogenesis and immunosuppression: cancer and other tales · Gregory T. Motz · 2011 · 490 citations · Cited by this paper
  18. Local Recurrence After Pancreatic Cancer Resection: A Multidisciplinary Review of Risk Factors and Potential Causes, Diagnostic Innovations, Emerging Therapeutic Frontiers, and Prevention Strategies · 2026 · Related
  19. The implications of IDH mutations for cancer development and therapy · Christopher J. Pirozzi · 2021 · 386 citations · Cited by this paper
  20. Dedifferentiated chondrosarcoma · 1995 · Related
  21. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial · Michael B. Atkins · 2018 · 375 citations · Cited by this paper
  22. Identification of a novel, recurrent HEY1‐NCOA2 fusion in mesenchymal chondrosarcoma based on a genome‐wide screen of exon‐level expression data · Lu Wang · 2011 · 349 citations · Cited by this paper
  23. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma · Pratistha Koirala · 2016 · 274 citations · Cited by this paper
  24. Advanced chondrosarcomas: role of chemotherapy and survival · Antoîne Italiano · 2013 · 258 citations · Cited by this paper
  25. Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas · Thomas F. DeLaney · 2014 · 247 citations · Cited by this paper
  26. Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European group · Robert John Grimer · 2007 · 234 citations · Cited by this paper
  27. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma · Patrick S. Tarpey · 2013 · 231 citations · Cited by this paper
  28. Dedifferentiated chondrosarcoma. A report of the clinicopathological features and treatment of seventy-eight cases. · Frank J. Frassica · 1986 · 214 citations · Cited by this paper
  29. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment · Judith V.M.G. Bovée · 2005 · 208 citations · Cited by this paper
  30. Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma · Zenon D. Konteatis · 2020 · 201 citations · Cited by this paper
  31. Dedifferentiated central chondrosarcoma · Eric L. Staals · 2006 · 192 citations · Cited by this paper
  32. Chondrosarcoma of the Pelvis · Maya E. Pring · 2001 · 191 citations · Cited by this paper
  33. Risk factors for survival and local control in chondrosarcoma of bone · Fabrice Fiorenza · 2002 · 183 citations · Cited by this paper
  34. Mesenchymal chondrosarcoma: Prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study · Anna Maria Frezza · 2014 · 180 citations · Cited by this paper
  35. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) · Michael J Wagner · 2021 · 168 citations · Cited by this paper
  36. Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma · William D. Tap · 2020 · 166 citations · Cited by this paper
  37. Chondrosarcoma of the pelvis: Prognostic factors for 67 patients treated with definitive surgery · Dhiren S. Sheth · 1996 · 165 citations · Cited by this paper
  38. Chondrosarcoma: biology, genetics, and epigenetics · Warren Allen Chow · 2018 · 153 citations · Cited by this paper
  39. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor · Scott M. Schuetze · 2016 · 138 citations · Cited by this paper

Source: OpenAlex (CC0)